Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

801. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. 10580457 1999 12 08 1999 12 08 2016 10 17 0098-7484 282 20 1999 Nov 24 JAMA JAMA Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. 1921-8 In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity (...) without adverse upper gastrointestinal (GI) tract effects that result from COX-1 inhibition. To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Randomized, multicenter, placebo-controlled, double-blind trial lasting 12 weeks, with follow-up at weeks 2, 6, and 12, from September 1996 thorugh February 1998. Seventy-nine clinical sites

JAMA1999

802. Combination therapy in rheumatoid arthritis: updated systematic review

Combination therapy in rheumatoid arthritis: updated systematic review Combination therapy in rheumatoid arthritis: updated systematic review Combination therapy in rheumatoid arthritis: updated systematic review Verhoeven A C, Boers M, Tugwell P Authors' objectives To undertake a second update of a systematic review of combination therapy in rheumatoid arthritis (see Other Publications of Related Interest nos.1-2). Searching MEDLINE was searched from August 1992 (the closing date for the last (...) review) to July 1997 using the MeSH terms 'arthritis, rheumatoid' and 'drug therapy, combination'. The bibliographies of all the retrieved studies were scrutinised, and the first authors of studies published only in abstract form were contacted; such studies were only eligible for inclusion if a full manuscript was available. Relevant articles published in English, French, German or Dutch were retrieved. Studies from the previous review that were rated as providing moderately strong or strong

DARE.1998

803. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK

Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK McCabe C J, Akehurst R L, Kirsch J, Whitfield M, Backhouse M, Woolf A D, Scott D L, Emery P, Haslock I Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Non-steroidal anti-inflammatory drugs (NSAIDs) for the management of rheumatoid arthritis and osteoarthritis: nabumetone (between 1,000 and 2,000 mg per day), diclofenac (100-200 mg per day), ibuprofen (1,200

NHS Economic Evaluation Database.1998

804. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone Cost-effectiveness and cost-utility of combination therapy in early rheumatoid (...) technology Combined step-down prednisolone, methotrexate and sulphasalazine versus sulphasalazine alone in the treatment of early rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Patients with early, active RA. Setting Hospital and primary care; the clinical study (COBRA) was conducted in 10 clinical centres, one in Belgium and the remainder in The Netherlands. The economic study was conducted

NHS Economic Evaluation Database.1998

805. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation

Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation Lambert C M, Hurst N P, Forbes J F, Lochhead A, MacLeod M, Nuki G Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using day care or inpatient care for active rheumatoid arthritis. The day care option involved receiving treatment in hospital between 10am and 4pm, complemented with treatment periods at home until no further clinical improvement

NHS Economic Evaluation Database.1998

806. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation.

Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. 9550954 1998 04 29 1998 04 29 2015 11 19 0959-8138 316 7136 1998 Mar 28 BMJ (Clinical research ed.) BMJ Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. 965-9 To test the clinical equivalence and resource consequences of day care with inpatient care for active rheumatoid arthritis (...) . Randomised controlled clinical trial with integrated cost minimisation economic evaluation. Rheumatic diseases unit at a teaching hospital between 1994 and 1996. 118 consecutive patients with active rheumatoid arthritis randomised to receive either day care or inpatient care. Clinical assessments recorded on admission, discharge, and follow up at 12 months comprised: the health assessment questionnaire, Ritchie articular index, erythrocyte sedimentation rate, hospital anxiety and depression scale

BMJ1998 Full Text: Link to full Text with Trip Pro

807. Efficacy of multidisciplinary team care programs in rheumatoid arthritis

Efficacy of multidisciplinary team care programs in rheumatoid arthritis Efficacy of multidisciplinary team care programs in rheumatoid arthritis Efficacy of multidisciplinary team care programs in rheumatoid arthritis Vliet Vlieland T P, Hazes J M Authors' objectives To assess the efficacy of multidisciplinary team care programmes in rheumatoid arthritis (RA). Searching MEDLINE was searched from 1966 to January 1997 using the search terms 'RA', 'rehabilitation', 'hospitalisation', 'ambulatory (...) team care programs in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1997; 27(2): 110-122 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Arthritis, Rheumatoid /rehabilitation /therapy; Controlled Clinical Trials as Topic; Delivery of Health Care /standards; Female; Humans; Inpatients; Male; Outpatients; Patient Care Team /standards; Program Evaluation; Randomized Controlled Trials as Topic AccessionNumber 11998005127 Date bibliographic record published 31/08/1999 Date

DARE.1997

808. Group education for rheumatoid arthritis patients

Group education for rheumatoid arthritis patients Group education for rheumatoid arthritis patients Group education for rheumatoid arthritis patients Taal E, Rasker J J, Wiegman O Authors' objectives To assess the effectiveness of group education programmes in improving the knowledge, behaviour and health status of patients with rheumatoid arthritis (RA). In addition, to evaluate the extent to which programmes fulfill certain criteria for educational self-management programmes. Searching (...) arthritis patients. Seminars in Arthritis and Rheumatism 1997; 26(6): 805-816 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Arthritis, Rheumatoid /psychology /therapy; Health Knowledge, Attitudes, Practice; Health Status Indicators; Humans; Patient Education as Topic /methods /standards; Program Evaluation AccessionNumber 11997000867 Date bibliographic record published 28/02/1999 Date abstract record published 28/02/1999 Record Status This is a critical abstract of a systematic review

DARE.1997

809. Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases

Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases Limited bone loss due to corticosteroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases Verhoeven A C, Boers M Authors' objectives To clarify the relationship between changes in bone density, the treated (...) classification criteria for RA. Specific interventions included in the review Corticosteroid therapy. Participants included in the review Three cohort types were included in the review. The first comprised a total of 66 patients with rheumatoid arthritis(RA) all of whom were taking corticosteroid therapy. The majority of these participants were post-menopausal women. Patients with both early and advanced RA were included. All patients were taking low-dose corticosteroids. The second cohort type comprised

DARE.1997

810. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. 9219699 1997 07 17 1997 07 17 2006 11 15 0028-4793 337 3 1997 Jul 17 The New England journal of medicine N. Engl. J. Med. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. 141-7 Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid arthritis, and antagonism of TNF may (...) reduce the activity of the disease. This study evaluated the safety and efficacy of a novel TNF antagonist - a recombinant fusion protein that consists of the soluble TNF receptor (p75) linked to the Fc portion of human IgG1 (TNFR:Fc). In this multicenter, double-blind trial, we randomly assigned 180 patients with refractory rheumatoid arthritis to receive subcutaneous injections of placebo or one of three doses of TNFR:Fc (0.25, 2, or 16 mg per square meter of body-surface area) twice weekly

NEJM1997

811. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. 9251634 1997 11 24 1997 11 24 2016 11 24 0140-6736 350 9074 1997 Aug 02 Lancet (London, England) Lancet Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. 309-18 The value of intensive combination therapy in early rheumatoid arthritis is unproven (...) . In a multicentre, double-blind, randomised trial (COBRA), we compared the combination of sulphasalazine (2 g/day), methotrexate (7.5 mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day) with sulphasalazine alone. 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were

Lancet1997

812. Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity

Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies (...) and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity Pladevall-Vila M, Delclos G L, Varas C, Guyer H, Brugues-Tarradellas J, Anglada-Arisa A Authors' objectives To analyse the differences among the studies and among the meta-analyses that consider the relationship between oral contraceptives and rheumatoid arthritis. Searching A search was made of MEDLINE and Science Citation Index, covering the years 1968 to 1993, and contact with experts in the field was made

DARE.1996

813. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness

Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness Saag K G, Criswell L A, Sems K M, Nettleman M D, Kolluri S Authors' objectives To compare the effectiveness of prednisolone to placebo and active drug controls, and to compare the relative (...) effectiveness of prednisolone to second line agents in the treatment of rheumatoid arthritis (RA). Searching Clinical studies published in the English language were identified by searching MEDLINE from 1966 to 1994 using the subject headings 'corticosteroids' and 'rheumatoid arthritis', and by handsearching Arthritis and Rheumatism and the Scandinavian Journal of Rheumatology from inception through 1994; all abstracts of Arthritis and Rheumatism over the past 15 years were also examined for unpublished

DARE.1996

814. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment

Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment Superio-Cabuslay E, Ward M M, Lorig K R (...) Authors' objectives To compare the effects of education interventions and non-steroidal anti-inflammatory drug (NSAID) treatment on pain and functional disability in patients with osteoarthritis, and on pain, functional disability, and tender joint counts in patients with rheumatoid arthritis. Searching Studies of educational interventions: MEDLINE was searched from 1966 to 1993 (the search terms are provided); bibliographies of relevant articles and of a previous meta-analysis were examined. Studies

DARE.1996

815. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis

The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis Al J A, Michel B C, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diclofenac plus misoprostol (50 mg + 200micrograms twice (tid) or three times (tid) daily) versusdiclofenac alone (50 mg bid or tid) in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients. Type

NHS Economic Evaluation Database.1996

816. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis

A cost effectiveness analysis of cyclosporine in rheumatoid arthritis A cost effectiveness analysis of cyclosporine in rheumatoid arthritis A cost effectiveness analysis of cyclosporine in rheumatoid arthritis Anis A H, Tugwell P X, Wells G A, Stewart D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of second line agents for the treatment of patients with severe rheumatoid arthritis (RA). Specifically the agents examined were the immunosupressants cyclosporine (CyA), D-penicillamine (D-pen) and azathioprine (Aza). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with severe rheumatoid arthritis eligible for treatment with a second line agent. Setting Hospital

NHS Economic Evaluation Database.1996

817. In- and out-patient rehabilitation in rheumatoid arthritis: a controlled open, longitudinal, cost-effectiveness study

In- and out-patient rehabilitation in rheumatoid arthritis: a controlled open, longitudinal, cost-effectiveness study In- and out-patient rehabilitation in rheumatoid arthritis: a controlled open, longitudinal, cost-effectiveness study In- and out-patient rehabilitation in rheumatoid arthritis: a controlled open, longitudinal, cost-effectiveness study Nordstrom D C, Konttinen Y T, Solovieva S, Friman C, Santavirta S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The rehabilitation of rheumatoid arthritis (RA) patients using an intensive, 21 day, multidisciplinary, community sponsored in-patient programme or a standard out-patient physiotherapy programme designed by the patient's rheumatologist. Type of intervention

NHS Economic Evaluation Database.1996

818. Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis (CENTRA): a decision analysis model

Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis (CENTRA): a decision analysis model Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis (CENTRA): a decision analysis model Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis (CENTRA): a decision analysis model Kavanaugh A, Heudebert G, Cush J, Jain R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of either a novel biological agent (BIO), methotrexate (MTX) or intramuscular gold (IMG) as a therapy for rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with established rheumatoid arthritis (RA). Setting The practice setting was the primary care sector

NHS Economic Evaluation Database.1996

819. Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis.

Misoprostol and gastrointestinal complications in patients taking nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Misoprostol and gastrointestinal ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1996 ) Volume: 124 , Issue: 10 , Pages: 926; author reply 927 Find this paper at: Abstract BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) use is increasingly recognized (...) as a major factor associated with peptic ulcer disease and complications. We undertook a multicenter, double-blind, placebo-controlled trial to evaluate efficacy and safety of nizatidine in preventing ulcer formation in patients with osteoarthritis who were taking NSAIDs. METHODS: After endoscopy to rule out the presence of an acute ulcer, 496 patients were randomized to receive nizatidine, 150 mg twice daily (248 patients) or placebo (248 patients) for 3 months. Repeated endoscopies were performed

Annals of Internal Medicine1996

820. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. 8598699 1996 04 23 1996 04 23 2015 06 16 0140-6736 347 8998 1996 Feb 10 Lancet (London, England) Lancet Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. 347-52 A favourable benefit/risk ratio for treatment of rheumatoid arthritis (RA) with second-line drugs has been established only in short-term studies. The present investigation addresses the question of whether (...) Lancet 2985213R 0140-6736 0 Anti-Inflammatory Agents, Non-Steroidal 0 Antirheumatic Agents AIM IM Lancet. 1996 Feb 10;347(8998):343-4 8598695 Anti-Inflammatory Agents, Non-Steroidal administration & dosage Antirheumatic Agents administration & dosage adverse effects Arthritis, Rheumatoid drug therapy epidemiology prevention & control Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Humans Incidence Life Tables Male Middle Aged Recurrence Risk Factors Severity of Illness Index

Lancet1996